Traders should monitor for potential regulatory filings or closing announcements. The addition of a novel IVL platform positions Stryker to capture share in the fast-growing calcium modification market, which could drive long-term revenue growth in the Peripheral Vascular segment.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $347.00entry
- T+1 · 7mo ago −0.33%α −1.54% · $345.86
- T+5 · 7mo ago −2.49%α −5.79% · $338.34
- T+20 · 6mo ago −18.58%α −26.30% · $282.54
- T+60 · 4mo ago −4.97%α −13.95% · $329.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Stryker announced a definitive agreement to acquire Amplitude Vascular Systems, a private developer of next-generation intravascular lithotripsy (IVL) technology for treating calcified peripheral arterial disease. The acquisition strengthens Stryker’s Peripheral Vascular portfolio and advances its strategy in arterial disease treatment, with the deal subject to customary closing conditions.
Key Facts
- Stryker is acquiring Amplitude Vascular Systems (AVS), a privately held company developing a next-generation IVL platform for calcified peripheral arterial disease.
- AVS’ technology uses pulsed CO₂-generated pressure waves via a balloon catheter to fracture calcium and improve luminal gain, enhancing deliverability and treatment efficiency.
- The acquisition expands Stryker’s Peripheral Vascular (PV) portfolio and supports its strategy to build a comprehensive PV platform.
- Transaction is subject to customary closing conditions; both companies will operate independently until closing.
- AVS was founded in 2017 and is backed by BioStar Capital, Cue Growth Partners, and other global investors.
Financial Impact
Undisclosed amount; likely mid- to high-hundreds of millions given strategic fit and technology stage.
Risk Factors
- Regulatory or antitrust delays could push back the close.
- Integration risk if AVS’ technology does not scale as expected.
- Potential for future dilution if financing is required, though none disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272439 |
Track record
29 reports on SYK
5 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +23.40% at T+20 after the Oct 7, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 12, 20266d ago Court Ruling Neutral 3/10 Entry $309.64 Now $310.72 +0.35% settles Dec 14
- Nov 9, 20268d ago 8-K Neutral 2/10 Entry $324.29 Now $310.72 −4.18% settles Dec 9
- Nov 5, 202612d ago 144 Neutral 3/10 Entry $325.87 Now $310.72 −4.65% settles Dec 7
- Nov 4, 202613d ago S-3ASR Neutral 3/10 Entry $335.08 Now $310.72 −7.27% settles Dec 4
- Nov 3, 202614d ago Institutional Cluster Mixed 3/10 Entry $310.55 Now $310.72 +0.05% settles Dec 2
- Oct 29, 202619d ago 8-K Bearish 6/10 No price data
- Oct 29, 202619d ago Press Release Bearish 6/10 Entry $291.86 Now $310.72 −6.46% settles Nov 30
- Oct 26, 202622d ago Press Release Neutral 4/10 Entry $306.13 Now $310.72 +1.50% settles Nov 23
- Oct 20, 202629d ago PTAB Trial Bearish 5/10 Entry $297.60 Now $310.72 −4.41% settles Nov 18
- Oct 7, 20265w ago ANALYST-UPGRADE Bullish 4/10 Entry $275.25 to $339.65 Now $310.72 +12.89% ▲ +23.40% +24.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers